A murine model of myeloma that allows genetic manipulation of the host microenvironment

DMM Disease Models and Mechanisms

Volumn 2, Issue 11-12, 2009, Pages 604-611

  Fowler, Jessica A ^a   Mundy, Gregory R ^a   Lwin, Seint T ^a   Lynch, Conor C ^a,b   Edwards, Claire M ^a  

^a VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^b VANDERBILT UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GELATINASE B; PROTEIN; RECOMBINATION ACTIVATING GENE 2; UNCLASSIFIED DRUG;

ARTICLE; B LYMPHOCYTE; BONE; BONE DISEASE; CONTROLLED STUDY; DNA MODIFICATION; FEMALE; GENETIC MANIPULATION; HISTOPATHOLOGY; HOST CELL; MICRO-COMPUTED TOMOGRAPHY; MICROENVIRONMENT; MOUSE; MYELOMA; MYELOMA CELL; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE; TUMOR GROWTH;

ANIMALS; BONE DISEASES; DISEASE MODELS, ANIMAL; DNA-BINDING PROTEINS; FEMALE; FEMUR; GENETIC TECHNIQUES; IMMUNOHISTOCHEMISTRY; MATRIX METALLOPROTEINASE 9; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; MULTIPLE MYELOMA; TIBIA; TOMOGRAPHY, X-RAY COMPUTED;

MURINAE; MUS;

EID: 70549107720     PISSN: 17548403     EISSN: 17548411     Source Type: Journal    
DOI: 10.1242/dmm.003160     Document Type: Article

References (24)

1. Asosingh, K., Radl, J., Van Riet, I., Van Camp, B. and Vanderkerken, K. (2000). The 5TMM seies: a useful in vivo mouse model of human multiple myeloma. Hematol. J. 1, 351-356.
2. Barille, S., Akhoundi, C., Collette, M., Mellerin, M. P., Rapp, M. J., Harousseau, J. L., Bataille, R. and Amiot, M. (1997). Metalloproteinases in multiple myeloma: production of matrix metalloproteinase-9 (MMP-9), activation of proMMP-2, and induction of MMP-1 by myeloma cells. Blood 90, 1649-1655. (Pubitemid 27355439)
3. Barille, S., Bataille, R., Rapp, M. J., Harousseau, J. L. and Amiot, M. (1999). Production of metalloproteinase-7 (matrilysin) by human myeloma cells and its potential involvement in metalloproteinase-2 activation. J. Immunol. 163, 5723-5728.
4. Budzynski, W. and Radzikowski, C. (1994). Cytotoxic cells in immunodeficient athymic mice. Immunopharmacol. Immunotoxicol. 16, 319-346. (Pubitemid 24285733)
5. Chesi, M., Robbiani, D. F., Sebag, M., Chng, W. J., Affer, M., Tiedemann, R., Valdez, R., Palmer, S. E., Haas, S. S., Stewart, A. K. et al. (2008). AID-dependent activation of a MYC transgene induces multiple myeloma in a conditional mouse model of post-germinal center malignancies. Cancer Cell 13, 167-180. (Pubitemid 351163163)
6. Croucher, P. I., Shipman, C. M., Lippitt, J., Perry, M., Asosingh, K., Hijzen, A., Brabbs, A. C., van Beek, E. J., Holen, I., Skerry, T. M. et al. (2001). Osteoprotegerin inhibits the development of osteolytic bone disease in multiple myeloma. Blood 98, 3534-3540.
7. Croucher, P. I., De Hendrik, R., Perry, M. J., Hijzen, A., Shipman, C. M., Lippitt, J., Green, J., Van Marck, E., Van Camp, B. and Vanderkerken, K. (2003). Zoledronic acid treatment of 5T2MM-bearing mice inhibits the development of myeloma bone disease: evidence for decreased osteolysis, tumor burden and angiogenesis, and increased survival. J. Bone Miner. Res. 18, 482-492. (Pubitemid 36241065)
8. Dallas, S. L., Garrett, I. R., Oyayobi, B. O., Dallas, M. R., Boyce, B. F., Bauss, F., Radl, J. and Mundy, G. R. (1999). Ibandronate reduces osteolytic lesions but not tumour burden in a murine model of myeloma bone disease. Blood 93, 1697-1706. (Pubitemid 29102498)
9. Edwards, C. M., Mueller, G., Roelofs, A. J., Chantry, A., Perry, M., Russell, R. G., Van Camp, B., Guyon-Gellin, Y., Niesor, E. J., Bentzen, C. L. et al. (2007). Apomine, an inhibitor of HMG-CoA-reductase, promotes apoptosis of myeloma cells in vitro and is associated with a modulation of myeloma in vivo. Int. J. Cancer 120, 1657-1663. (Pubitemid 46399350)
10. Edwards, C. M., Edwards, J. R., Lwin, S. T., Esparza, J., Oyajobi, B. O., McCluskey, B., Munoz, S., Grubbs, B. and Mundy, G. R. (2008). Increasing Wnt signaling in the bone marrow microenvironment inhibits the development of myeloma bone disease and reduces tumor burden in bone in vivo. Blood 111, 2833-2842.
11. Filgueira, L. (2004). Fluorescence-based staining for tartrate-resistant acidic phosphatase (TRAP) in osteoclasts combined with other fluorescent dyes and protocols. J. Histochem. Cytochem. 52, 411-414.
12. Garrett, I. R., Dallas, S., Radl, J. and Mundy, G. R. (1997). A murine model of human myeloma bone disease. Bone 20, 515-520. (Pubitemid 27270464)
13. Jemal, A., Tiwari, R. C., Murray, T., Ghafoor, A., Samuels, A., Ward, E. and Feuer Thun, M. J. (2004). Cancer Statistics, 2004. CA Cancer J. Clin. 54, 8-29.
14. Oyajobi, B. O., Franchin, G., Williams, P. J., Pulkrabek, D., Gupta, A., Munoz, S., Grubbs, B., Zhao, M., Chen, D., Sherry, B. et al. (2003). Dual effects of macrophage inflammatory protein-1alpha on osteolysis and tumor burden in the murine 5TGM1 model of myeloma bone disease. Blood 102, 311-319. (Pubitemid 36759670)
15. Oyajobi, B. O., Munoz, S., Kakonen, R., Williams, P. J., Gupta, A., Wideman, C. L., Story, B., Grubbs, B., Armstrong, A., Dougall, W. C. et al. (2007). Detection of myeloma in skeleton of mice by whole-body optical fluorescence imaging. Mol. Cancer Ther. 6, 1701-1708. (Pubitemid 46954046)
16. Radl, J., de Glopper, E., Schuit, H. E. R. and Zurcher, C. (1979). Idiopathic paraprotienemia II. Transplantation of the paraprotein-producing clone from old to young C587Bl/KaLwRij mice. J. Immunol. 122, 609-613. (Pubitemid 9089221)
17. Radl, J., Croese, J. W., Zurcher, C., Van Den Enden-Vieveen, M. H. M. and Margreet de Leeuw, A. (1988). Animal model of human disease; multiple myeloma. Am. J. Pathol. 132, 593-597.
18. Shinkai, Y., Rathbun, G., Lam, K. P., Oltz, E. M., Stewart, V., Mendelsohn, M., Charron, J., Datta, M., Young, F., Stall, A. M. et al. (1992). RAG-2-deficient mice lack mature lymphocytes owing to inability to initiate V(D)J rearrangement. Cell 68, 855-867.
19. Vacca, A., Ribatti, D., Iurlaro, M., Albini, A., Minischetti, M., Bussolino, F., Pellegrino, A., Ria, R., Rusnati, M., Presta, M. et al. (1998). Human lymphoblastoid cells produce extracellular matrix-degrading enzymes and induce endothelial cell proliferation, migration, morphogenesis, and angiogenesis. Int. J. Clin. Lab. Res. 28, 55-68. (Pubitemid 28228791)
20. Vacca, A., Ribatti, D., Presta, M., Minischetti, M., Iurlaro, M., Ria, R., Albini, A., Bussolino, F. and Dammacco, F. (1999). Bone marrow neovascularization, plasma cell angiogenic potential, and matrix metalloproteinase-2 secretion parallel progression of human multiple myeloma. Blood 93, 3064-3073. (Pubitemid 29200799)
21. Van Valckenborgh, E., Mincher, D., Di Salvo, A., Van Riet, I., Young, L., Van Camp, B. and Vanderkerken, K. (2005). Targeting an MMP-9-activated prodrug to multiple myeloma-diseased bone marrow: a proof of principle in the 5T33MM mouse model. Leukemia 19, 1628-1633. (Pubitemid 43090408)
22. Yaccoby, S., Barlogie, B. and Epstein, J. (1998). Primary myeloma cells growing in SCID-hu mice: a model for studying the biology and treatment of myeloma and its manifestations. Blood 92, 2908-2913. (Pubitemid 28469106)
23. Yaccoby, S., Wezeman, M. J., Henderson, A., Cottler-Fox, M., Yi, Q., Barlogie, B. and Epstein, J. (2004). Cancer and the microenvironment:Myeloma- osteoclast interactions as a model. Cancer Res. 64, 2016-2023.
24. Yaccoby, S., Ling, W., Zhan, F., Walker, R., Barlogie, B. and Shaughnessy, J. D., Jr (2007). Antibody-based inhibition of DKK1 suppresses tumor-induced bone resorption and multiple myeloma growth in vivo. Blood 109, 2106-2111.